A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease.

@article{Kieburtz2013ARD,
  title={A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease.},
  author={K. Kieburtz and G. Landwehrmeyer and M. Cudkowicz and E. Dorsey and A. Feigin and V. Hunt and E. Kayson and M. Mcdermott and S. Noonberg and W. Seitz and P. Soliveri and F. Walker and Burgunder J-M. and I. Romero and A. Magara and Y. Stebler and H. Rickards and J. Wright and J. D. Souza and R. Barker and S. Mason and A. D. Pietro and A. Goodman and D. O'Keeffe and M. Langlois and G. Ferland and L. Verret and S. Chouinard and S. Paris and C. Lepage and A. Nemeth and C. Merritt and C. Cox and T. Astbury and S. Murphy and Anwar Ahmed and P. S. Marie and R. A. Berila and C. Kubu and V. Segro and R. Kumar and D. Erickson and J. Schneiders and S. Frucht and Paula Wasserman and C. Moskowitz and B. Scott and P. Perry-Trice and S. Wyne and D. Parida and V. Redaelli and W. Sołtan and P. Robowski and M. Nowak and M. Schinwelski and A. Dziadkiewicz and T. Andrews and D. Ruddy and A. Dougherty and K. Boelmans and J. Schmalfeld and A. Muenchau and S. Zittel and W. Mallonee and G. Suter and J. Tan and L. Seeberger and Jenny Harris and J. Champion and J. Wojcieszek and J. Belden and Kathy Price and M. Hughes-Gay and G. Sprehn and F. Squitieri and T. Martino and F. Gregorio and A. D. Nicola and F. Elifani and A. Rosenblatt and N. Yoritomo and R. Margolis and P. Nichols and S. P{\aa}lhagen and A. Hoglund and M. Paucar and T. W. Reza-Soltani and A. Beister and T. Raab and J. Kieni and C. Schrenk and K. Banaszkiewicz and J. Misztela and M. W{\'o}jcik and E. Szczygieł and M. Golosz and M. Rudzinska and Roos Rac. and van den Bogaard Sja. and R. Bos and S. J. Booij and C. Hyson and J. Megens and E. Makaji and M. Jenkins and S. Hersch and S. Maya and C. Dresser and D. Rosas and K. Blindauer and C. Schindler and S. Hung and A. McNees and S. Tabrizi and M. Novak and M. Say and Anil D. Patel and P. Panegyres and N. Lewis and S. Jukich and C. Faull and L. Hjermind and O. Jakobsen and A. Vogel and T. Nielsen and J. Nielsen and S. Kostyk and A. Seward and P. Agrawal and J. Kraakevik and P. Hogarth and A. Wilson and J. Lear and P. Kraus and C. Saft and T. Steiner and R. Hoffmann and C. Stamm and J. Schollhammer and I. Uhl and B. Kaminski and K. O'Donovan and O. Quarrell and L. Nevitt and C. Kipps and A. Hare and K. Gunner and E. Hayward and M. Nance and J. Hamerlinck and C. Wielinski and O. Yastrubetskaya and E. Chiu and P. Chua and B. Mannaa and M. Tommaso and C. Serpino and C. Cormio and V. Sciruicchio and G. Michele and L. Maio and C. Russo and F. Sacc{\`a} and E. Salvatore and T. Tucci and M. Wolz and L. Klingelhoefer and A. Wolz and S. Schmidt and A. Storch and E. Spruth and S. Thiel and B. Neumann and H. Gelderblom and J. Priller and C. Sass and D. Probst and C. Werner and B. Leavitt and A. Coleman and L. Raymond and V. Wheelock and T. Tempkin and K. Baynes and N. Hermanowicz and Shari Niswonger and M. Haske-palomino and Y. Bordelon and A. Gratiano and A. Johnson and J. Corey-Bloom and J. Goldstein and G. Peavy and M. Geschwind and J. Gooblar and C. Barton and H. Fernandez and Ramon Rodriguez and M. Suelter and M. Daniels and J. Romrell and C. Swartz and L. Beglinger and E. Epping and E. Waterman and Megan M. Smith and R. Dubinsky and H. Dubinsky and C. Gray and D. Craufurd and E. Howard and M. Jones and H. Murphy and K. Anderson and C. Nickerson and J. Santo and T. Rigaud and N. Zappala and B. Robottom and C. Singer and M. Quesada and K. Rodriguez-Spengler and R. H. Cardenach{\'e} and R. Reilmann and S. Bohlen and H. E-M. and A. Colcher and H. Maccarone and L. Altin and A. Siderowf and T. Greenamyre and N. Lucarelli and L. Ivan{\vc}o and F. Marshall and C. Hickey and L. Deuel and K. Biglan and S. S{\"u}ssmuth and M. Orth and S. Trautmann and C. Eschenbach and A. Samii and Alma Macaraeg and D. Zielonka and A. Ciesielska and J. Marcinkowski and J. Sempołowicz and H. Karaskiewicz and C. O'Neill and I. Haq and G. Witkowski and J. Antczak and R. Rola and P. Richter and M. Rakowicz and K. Jachińska and S. Criswell and P. Deppen and K. Wharton and N. Mahant and E. McCusker and J. Griffith and C. Loy and L. Stewart and D. Fisher and D. Holt and C. Orme and A. Watts and J. Weber and K. White and R. Hauser and R. Albin and C. Coffey and W. Fischer and J. Miyasaki and Investigators Horizon.},
  journal={JAMA neurology},
  year={2013},
  volume={70 1},
  pages={
          25-33
        }
}
BACKGROUND Latrepirdine is an orally administered experimental small molecule that was initially developed as an antihistamine and subsequently was shown to stabilize mitochondrial membranes and function, which might be impaired in Huntington disease. OBJECTIVE To determine the effect of latrepirdine on cognition and global function in patients with mild to moderate Huntington disease. DESIGN Randomized, double-blind, placebo-controlled study. SETTING Sixty-four research centers in Australia… Expand
Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial
TLDR
PBT2 was generally safe and well tolerated in patients with Huntington's disease and the potential benefit on executive function will need to be confirmed in a larger study. Expand
The most appropriate primary outcomes to design clinical trials on Huntington's disease: meta‐analyses of cohort studies and randomized placebo‐controlled trials
TLDR
TMS and TFC are the most appropriate outcomes to design RCTs on HD likewise the verbal fluency test for cognition, and an effect of placebo administration on the total functional capacity is suggested. Expand
Mitochondrial Pharmacology of Dimebon (Latrepirdine) Calls for a New Look at its Possible Therapeutic Potential in Alzheimer’s Disease
TLDR
It seems worthwhile to reevaluate the clinical data to proof that clinical response is correlated with high levels of Neuropsychiatric Symptoms as these show a good relationship to the individual speed of symptomatic decline in AD patients related to mitochondrial dysfunction. Expand
Rifampicin for multiple system atrophy
TLDR
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis and the use of mitoxantrone for the treatment of multiple sclerosis: clinical and MRI outcomes of a multicenter controlled trial. Expand
Natural history of Huntington disease.
TLDR
Over 3 years, the cardinal features of Huntington disease all declined in a monotonic manner and may inform the design of trials aimed at reducing its burden. Expand
Clinical diagnosis and management in early Huntington’s disease: a review
TLDR
Although there is no cure of HD and management is limited, motor and psychiatric symptoms often respond to pharmacotherapy, and nonpharmacological approaches as well as supportive care are essential. Expand
New symptomatic therapies for Huntington disease.
TLDR
There is a lack of HD-specific evidence on effective treatments for behavioral and psychiatric symptoms, and a new set of mechanistic targets will become the focus of HD symptomatic therapies. Expand
Cognitive assessment in Huntington disease clinical drug trials.
TLDR
This chapter considers the role of cognition in clinical trial endpoint models, including a review of previous HD clinical trials that have included cognitive measures, and describes a general framework for selecting patient-based outcomes in clinical trials, which applies to the selection of cognitive outcomes. Expand
Maximizing placebo response in neurological clinical practice.
TLDR
The placebo effect is a widely recognized phenomenon in clinical research, with a negative perception that it could hide the "true" drug effect, and a recent expert consensus regarding placebo use in the clinic is a first step to future guidelines necessary to this field. Expand
Dimebon™: a promising neurodegenerative disease therapeutic with a problematic clinical history
TLDR
The history of Dimebon in the clinic and at the bench, recently proposed mechanism(s) of action of DIMEbon and what the future may hold for this drug with a troubled history are discussed. Expand
...
1
2
3
4
5
...